BGLC Stock Forecast: BioNexus Gene Lab Corp. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 16 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores BioNexus Gene Lab Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (83): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (3): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BGLC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BGLC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
BGLC appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BGLC vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, BioNexus Gene Lab Corp. returned −85.8% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BGLC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.6×
- Price / book
- 0.2×
- EV / EBITDA
- —
Cheaper than 75% of US stocks
Cheaper than 94% of US stocks
- Revenue growth (YoY)
- −96.6%
- Earnings growth (YoY)
- —
- Gross margin
- 17.0%
- Operating margin
- −88.2%
- Net margin
- −82.4%
Higher than 2% of US stocks
Higher than 17% of US stocks
Higher than 15% of US stocks
Higher than 7% of US stocks
- Return on equity
- −33.7%
- Return on assets
- −19.0%
- Dividend yield
- —
Higher than 27% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
BioNexus Gene Lab Corp. has a market value of $2.0M.
Revenue in the twelve months to 30 June 2026: $3.1M. The latest quarter shrank 96.6% year on year.
Net income over the same four quarters: −$2.6M, a −82.4% net margin.
Free cash flow in the twelve months to 30 June 2026: −$854K.
BioNexus Gene Lab Corp. employs 19 people — $165K of revenue per employee.
Data provided by Twelve Data
BGLC and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at BGLC’s peer groups, ranked by the model: industrial stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own BioNexus Gene Lab Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about BGLC
How does Ticker Nerd's model rank BGLC?
As at 21 Nov 2026, BioNexus Gene Lab Corp. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (83 of 100).
What is the BGLC stock forecast for 2030?
No analyst covering BioNexus Gene Lab Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BGLC are extrapolating price history, which says nothing about the business.
How has BGLC stock performed over the past year?
BioNexus Gene Lab Corp. returned -85.8% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does BioNexus Gene Lab Corp. do?
BioNexus Gene Lab Corp. is a biotechnology and specialty chemicals company based in Kuala Lumpur, Malaysia. The company operates through business segments that include industrial chemical trading and genomic screening services.
About BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp. is a biotechnology and specialty chemicals company based in Kuala Lumpur, Malaysia. The company operates through business segments that include industrial chemical trading and genomic screening services. Through its subsidiaries, it supplies chemical raw materials used in industrial, medical, appliance, automotive, mechanical, and electronic manufacturing across Southeast Asia. BioNexus Gene Lab Corp. also develops blood-based diagnostic services that apply functional genomics and RNA analysis to support early disease detection and personalized health management. Its business model combines distribution of specialty materials with laboratory-focused healthcare solutions, positioning the company at the intersection of industrial supply chains and precision diagnostics. This mix gives BioNexus Gene Lab Corp. a role in both regional manufacturing markets and emerging molecular testing services.
CEO Mr. Su-Leng Tan · 19 employees · Malaysia · https://www.bionexusgenelab.com